J. Sorensen
Chief Executive Officer at GALERA THERAPEUTICS, INC.
Net worth: 68 733 $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Chris Degnan | M | 44 | 5 years | |
| Robert Beardsley | M | 63 | 15 years | |
| Jennifer Stacey | F | 59 | 3 years | |
| Michael Powell | M | 69 | 8 years | |
| Kevin Lokay | M | 67 | 5 years | |
| Linda West | F | 64 | 4 years | |
| Dennis P. Riley | M | - | 15 years | |
| Lawrence Alleva | M | 74 | 5 years | |
| Owen Sorensen | M | - |
PlanetVerify Ltd.
 PlanetVerify Ltd. Packaged SoftwareTechnology Services PlanetVerify Ltd. provides electronic monetary transactions services. The company was founded by Owen Sorensen, Farmar Sean, and Heather Kennedy in 2013 and is headquartered in Dublin, Ireland. | 11 years |
| Heather Kennedy | F | - |
PlanetVerify Ltd.
PlanetVerify Ltd. Packaged SoftwareTechnology Services PlanetVerify Ltd. provides electronic monetary transactions services. The company was founded by Owen Sorensen, Farmar Sean, and Heather Kennedy in 2013 and is headquartered in Dublin, Ireland. | 11 years |
| Eric Forman | M | 44 | 11 years | |
| Emmett Cunningham | M | 63 | 6 years | |
| Shao Meng Wang | M | 60 |
Oncopia Therapeutics, Inc.
 Oncopia Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Oncopia Therapeutics LLC engages in biotechnology research. The company was founded in 2017 and is headquartered in Malvern, PA. | - |
| Eric Qun Zhao | M | - |
Oncopia Therapeutics, Inc.
Oncopia Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Oncopia Therapeutics LLC engages in biotechnology research. The company was founded in 2017 and is headquartered in Malvern, PA. | - |
| Andie Collier | F | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Joel F. Sussman | M | 75 |
Ascenta Therapeutics, Inc.
 Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | - |
| Campbell Murray | M | 48 | 7 years | |
| Jason Fuller | M | 46 | - | |
| Kathleen P. Mullinix | M | 80 | - | |
| Thomas Dyrberg | M | 69 | - | |
| Jon T. Holmlund | M | 67 |
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | 14 years |
| Robert B. Royds | M | 79 | 8 years | |
| Henning Thorsen | M | - | - | |
| Eugene Kennedy | M | 55 | 1 years | |
| Jay Stoudemire | M | - |
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | 3 years |
| Jeffrey Brill | M | - |
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | 12 years |
| Arthur Fratamico | M | 58 | - | |
| Stephen K. Carter | M | 85 | 3 years | |
| Ming Guo | M | 67 |
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | 5 years |
| Lance Leopold | M | - |
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | - |
| Norman Selby | M | 71 |
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | 4 years |
| Frank Torti | M | 45 | - | |
| Michael Barrett | M | 81 | - | |
| Henry Skinner | M | 60 | - | |
| Mark Bachleda | M | - | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 33 | 94.29% |
| Ireland | 2 | 5.71% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- J. Sorensen
- Personal Network
